@entity189 of the @entity1347 : a newly described association with XXXX .

@entity1204 @entity1 @entity6756 @entity4309 @entity5 @entity1347 @entity189 @entity3 @entity420 @entity4348
PURPOSE: @entity1204 in the @entity1347 ( @entity1347 ) is a poorly described @entity5 that can be clinically confused with @entity189 . We performed a case-comparison study to document the clinicopathologic characteristics of @entity5 and their association with risk factors for @entity1204 . @entity1 AND METHODS: The clinical records and pathology reports from @entity1 who underwent hysterectomy at our institution for @entity1204 over an 11-year interval were reviewed. The @entity1347 group consisted of @entity1 with @entity1204 that clearly originated between the lower uterine corpus and the upper endocervix. Immunohistochemistry and microsatellite instability and @entity6756 methylation assays were performed. RESULTS: Thirty-five (3.5%) of 1,009 @entity1 had @entity1204 of the @entity1347 . Compared with @entity1 with @entity5 , @entity1347 @entity1 were younger, had higher stage @entity5 , and had more @entity3 . Preoperative diagnosis of the @entity5 more frequently included the possibility of @entity420 . Seventy-three percent of the @entity5 had an immunohistochemical expression pattern typical of conventional @entity4348 . Ten (29%) of 35 @entity1 with @entity5 were confirmed to have @entity4309 or were strongly suspected to have @entity4309 on the basis of tissue-based molecular assays. CONCLUSION: The prevalence of @entity4309 in @entity1 with @entity1347 @entity1204 (29%) is much greater than that of the general @entity1204 @entity1 population (1.8%) or in @entity1204 @entity1 younger than age 50 years (8% to 9%). On the basis of our results, the possibility of @entity4309 should be considered in @entity1 with @entity5 .
